IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.182
AS - Asia 5.684
EU - Europa 2.600
SA - Sud America 1.275
AF - Africa 134
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 23
Totale 17.923
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.839
SG - Singapore 2.597
CN - Cina 1.266
IT - Italia 1.195
BR - Brasile 967
IN - India 580
VN - Vietnam 573
GB - Regno Unito 335
SE - Svezia 332
DE - Germania 262
CA - Canada 243
HK - Hong Kong 136
BD - Bangladesh 111
AR - Argentina 107
FI - Finlandia 96
ID - Indonesia 80
NL - Olanda 64
MX - Messico 59
EC - Ecuador 53
IQ - Iraq 49
RU - Federazione Russa 49
ZA - Sudafrica 43
UA - Ucraina 41
CO - Colombia 39
PK - Pakistan 39
FR - Francia 37
ES - Italia 34
JP - Giappone 33
JO - Giordania 32
PY - Paraguay 30
RO - Romania 30
SA - Arabia Saudita 29
TR - Turchia 26
VE - Venezuela 26
CL - Cile 23
EG - Egitto 22
EU - Europa 22
PL - Polonia 21
IR - Iran 19
AU - Australia 17
PE - Perù 16
AT - Austria 15
CZ - Repubblica Ceca 15
KE - Kenya 14
MA - Marocco 14
MY - Malesia 13
AE - Emirati Arabi Uniti 12
LT - Lituania 11
IE - Irlanda 10
NG - Nigeria 10
PT - Portogallo 10
TN - Tunisia 10
UZ - Uzbekistan 10
EE - Estonia 9
UY - Uruguay 9
PH - Filippine 8
AZ - Azerbaigian 7
ET - Etiopia 7
IL - Israele 7
KR - Corea 7
LB - Libano 7
BG - Bulgaria 6
GT - Guatemala 6
HN - Honduras 6
DO - Repubblica Dominicana 5
KZ - Kazakistan 5
NP - Nepal 5
AL - Albania 4
CH - Svizzera 4
CR - Costa Rica 4
CU - Cuba 4
CY - Cipro 4
HR - Croazia 4
NZ - Nuova Zelanda 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
BO - Bolivia 3
DZ - Algeria 3
GE - Georgia 3
JM - Giamaica 3
LK - Sri Lanka 3
PA - Panama 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
GR - Grecia 2
GY - Guiana 2
HU - Ungheria 2
KG - Kirghizistan 2
KI - Kiribati 2
KW - Kuwait 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
OM - Oman 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
Totale 17.905
Salva come PNG Salva come JPEG
Città #
San Jose 1.659
Chandler 826
Singapore 805
Ashburn 740
Santa Clara 444
Hefei 399
Bengaluru 396
Dallas 385
Milan 368
Lawrence 351
Princeton 351
Chicago 246
Ho Chi Minh City 221
London 221
Beijing 201
Munich 198
Wilmington 190
Ottawa 160
Hong Kong 126
Des Moines 118
Catanzaro 110
Hanoi 108
São Paulo 87
Los Angeles 80
New York 73
Turku 66
Boardman 62
Shanghai 47
Rome 46
Naples 38
Council Bluffs 37
Pune 35
Rio de Janeiro 35
Norwalk 34
Guangzhou 31
Brooklyn 30
San Francisco 30
Haiphong 29
Helsinki 29
Da Nang 28
Montreal 28
Redmond 28
The Dalles 27
Chennai 24
Amman 23
Tokyo 23
Redwood City 22
Warsaw 22
Manchester 21
Thái Bình 20
Atlanta 19
Curitiba 19
Dhaka 19
Baghdad 18
Jeddah 18
Mexico City 18
Orem 18
Parma 18
Phoenix 17
Columbus 16
San Nicola Manfredi 16
Shenzhen 16
Stockholm 16
Amsterdam 15
Biên Hòa 15
Guayaquil 15
Johannesburg 15
Porto Alegre 15
Toronto 15
Horia 14
Salvador 14
Seattle 14
Belo Horizonte 13
Quito 13
Reggio Calabria 13
Augusta 12
Aversa 12
Buffalo 12
Cape Town 12
Carbonia 12
Cosenza 12
Nairobi 12
Palermo 12
Spezzano della Sila 12
Boston 11
Campinas 11
Charlotte 11
Delhi 11
Denver 11
Frankfurt am Main 11
Hanover 11
Jakarta 11
Madrid 11
Mountain View 11
Olomouc 11
Recife 11
Ankara 10
Brasília 10
Guarulhos 10
Las Vegas 10
Totale 10.357
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 487
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 142
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 117
miR-22 suppresses DNA ligase III addiction in multiple myeloma 103
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 100
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 99
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 94
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 89
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 88
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 87
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 86
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 82
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 80
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 79
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 79
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 78
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 77
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 76
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 75
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 75
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 75
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 75
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 74
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 74
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 73
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 73
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 73
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 73
Fetal ontogeny and tumor expression of the early thymic antigen UN1 72
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 71
Mir-34: a new weapon against cancer? 71
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 71
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 70
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 70
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 69
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 69
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 69
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 68
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 67
POLYAMINE UPTAKE BY HUMAN COLON-CARCINOMA CELL-LINE CACO-2 67
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 66
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 66
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 65
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 65
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 64
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 63
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 63
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 63
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 62
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 62
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 60
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 60
Mir-221/222 are promising targets for innovative anticancer therapy 60
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo 60
miR-221/222 inhibitors for the treatment of multiple myeloma 60
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 60
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 59
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 59
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 59
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
Anti-myeloma activity of miR-125 mimics 59
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 58
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 58
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 58
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 58
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 58
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 57
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 57
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 57
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 57
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 57
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 57
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 57
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 57
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 56
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 56
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 56
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 56
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 56
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma 56
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 56
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 55
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 55
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 55
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 55
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 55
The non-coding RNA landscape of plasma cell dyscrasias 55
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. 54
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 54
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 54
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 54
Totale 7.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 182.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 182.903
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 0 6
2021/2022979 19 6 12 286 57 19 31 202 96 92 146 13
2022/20232.607 722 77 85 210 279 230 13 167 395 162 217 50
2023/20241.366 311 135 116 94 98 321 41 53 15 48 61 73
2024/20254.168 563 250 184 127 234 521 108 155 486 267 423 850
2025/20268.431 412 897 819 1.510 850 326 1.174 486 1.003 566 275 113
Totale 18.221